Mary D. Whiteman

home / authors / mary-d-whiteman

Articles

A Case Study for the Inactivation of TSE Agents: Using an Alkaline Treatment in the Manufacturing Process of a Cell Culture Media Supplement

A Case Study for the Inactivation of TSE Agents: Using an Alkaline Treatment in the Manufacturing Process of a Cell Culture Media Supplement

Mary D. Whiteman;Gail Sofer;Joseph G. Montalto
September 1st 2003

Biopharmaceuticals are perceived as being at risk of transmitting spongiform encephalopathies to patients, although there has never been such an incident. Clearance studies such as the one described in this article (using a TSE model) can validate inactivation and enhance confidence in the safety of therapeutics produced using animal-derived cell culture supplements.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: March 25th 2024 | Updated: January 30th 2025
Building Velocity into Fill/Finish Timelines: Your Guide to Quality and Regulatory Success in the CDMO Space
Published: June 10th 2024 | Updated: January 30th 2025
Lab Logic: Decoding Analytical Testing for Optimal Product Development
Published: June 24th 2024 | Updated: January 30th 2025
All Things mRNA: Strategies for Effective mRNA Vaccine and Therapeutic Development
Published: October 7th 2024 | Updated: January 30th 2025
Practical Guide: Mastering Process Validation and Quality Control to Produce Products that Scale from Clinic to Commercial
© 2025 MJH Life Sciences

All rights reserved.